Seaport Therapeutics Inc. (SPTX:NASDAQ) closed at $21.97 on November 10, 2026, up 0.21% on the day. The stock trades 22.6% below its 52-week high of $28.38 and 47.9% above its 52-week low of $14.85. Over the past year, it gained 10.5%. Seaport Therapeutics Inc. is part of the Health Care sector.
In 133 trading sessions since May 4, 2026, SPTX closed higher on 72 days (54%). Its best day was July 8, 2026 (+16.62%) and its worst was May 4, 2026 (-14.31%). The stock moved 10% or more in a single session 4 times. It opened at least 5% above the previous day's high 1 time.
Seaport Therapeutics is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. Through its differentiated approach, the Company identifies clinically validated mechanisms with established efficacy and safety which had historically been limited by high first-pass metabolism, low bioavailability, and/or side effects. Seaport applies its proprietary GlyphTM platform to overcome those limitations and invent innovative oral therapies. With an experienced team of industry leaders, Seaport has a proven track record in neuropsychiatry drug discovery and development and delivering successful business outcomes. Seaport aims to develop novel, leading treatment options that will make a significant impact for patients and their families.
Find more stocks like SPTX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.